**[CURRICULUM VITAE]{.underline}**

[Personal]{.underline}:

Name: Michael R. Bishop, M.D., F.A.C.P

Home Address and Phone No.: 14015 Weeping Cherry Drive

Rockville, MD 20850

Phone: (301) 545-0454

FAX: (301) 545-0455

Office Address and Phone No.: National Institute of Health

National Cancer Institute

Building 10, CRC/Room 4-3152

10 Center Drive, MSC 1906

Bethesda, MD 20892-1906

Phone: (301) 435-4654

Phone: (301) 435-2764

FAX: (301) 480- 3444

E-mail: mbishop@mail.nih.gov

Birth Date and Place: April 3, 1959

Eldorado, Illinois

[Education]{.underline}:

1981 B.S. (Biology - Ecology, Ethology, and Evolution)

University of Illinois -- Urbana-Champaign

Urbana-Champaign, Illinois

1985 M.D.

University of Illinois College of Medicine

Chicago, Illinois

Post-Degree Training:

1985 - 1986 Internship, Internal Medicine

Northwestern Memorial Hospital

Chicago, Illinois

1986 -- 1988 Residency, Internal Medicine

Northwestern Memorial Hospital

Chicago, Illinois

1988 - 1991 Fellowship, Hematology/Oncology

Loyola University Medical Center

Maywood, Illinois

[Academic Appointments:]{.underline}

6/2007 - present Senior Investigator (Tenured)

National Cancer Institute

National Institutes of Health

Bethesda, MD

8/2005 -- 4/2007 Deputy Branch Chief (acting)

\- Director, Medical Oncology Fellowship Program

\- Chief, Medical Oncology Clinical Services

\- Head, Office of Protocol Administration

\- Head, Office of Research Nursing

Medical Oncology Branch

Center for Cancer Research

National Cancer Institute

National Institutes of Health

Bethesda, MD

3/1999 -- 5/2007 Investigator (Tenure Track)

National Cancer Institute

National Institutes of Health

Bethesda, MD

3/1999 -- present Clinical Head

Experimental Transplantation

And Immunology Branch

Center for Cancer Research

National Cancer Institute

National Institutes of Health

Bethesda, MD

7/1997 - 2/1999 Associate Professor of Medicine

Section of Oncology/Hematology

University of Nebraska Medical Center

Omaha, Nebraska

7/1997 - 2/1999 Associate Professor of Pediatrics (Courtesy)

Section of Pediatric Hematology/Oncology

University of Nebraska Medical Center

Omaha, Nebraska

1997 - 2/1999 Program Member, Developmental Therapeutics

University of Nebraska Medical Center-Eppley Cancer Center

Omaha, Nebraska

1992 - 7/1997 Assistant Professor of Medicine

Section of Oncology/Hematology

University of Nebraska Medical Center

Omaha, Nebraska

Assistant Professor of Pediatrics (Courtesy)

Section of Pediatric Hematology/Oncology

University of Nebraska Medical Center

Omaha, Nebraska

Assistant Professor (Courtesy)

Eppley Institute for Research in Cancer and Allied Diseases University
of Nebraska Medical Center

Omaha, Nebraska

1995 -- 2/1999 Graduate Faculty Member

University of Nebraska Medical Center

Omaha, Nebraska

1991 - 1992 Assistant Professor of Medicine

Section of Hematology/Oncology

University of Kentucky Medical Center

Lexington, Kentucky

[Board Certification and Medical License:]{.underline}

Diplomate, American Board of Internal Medicine - Internal Medicine

Diplomate, American Board of Internal Medicine - Oncology

Eligible, American Board of Internal Medicine - Hematology

Illinois #036-074246 (inactive)

Kentucky #28340 (inactive)

Nebraska #18909 (active)

[Grants/Contracts:]{.underline}

7/1/98 - 6/30/99 "BCR/ABL Positivity of Early Stem Cells from CML
Patients"

Funding source, Nebraska Dept. of Health and Human Services

Funding source, Nebraska Department of Health, LB506

Cost of entire project \$29,658

PI: Dr. John Jackson

Co-I: Dr. Bishop

1/28/98 - 7/31/98 "Phase 1B Safety Study of 1B-367 Given to Patients
Receiving Myeloablative Chemotherapy Who Are Undergoing Bone Marrow or
Peripheral Blood Stem Cell Transplantation and at Risk for Developing
Oral Mucositis"

Funding source, Intrabiotics

Cost of entire project \$26,400

Co-PI's: Dr. Eilers and Dr. Bishop

Co-I's: Drs. Armitage, Bierman, Kessinger, Reed, Tarantolo, Tempero,
Vose

4/1/98 - 3/31/99 "A Comparison of G-CSF with the Combination of G-CSF
and GM-CSF for the Mobilization of Progenitor Cells and Dendritic Cells
in Normal Individuals"

Funding source, Immunex Corporation

Cost of entire project \$50,000

PI: Dr. Bishop

11/97 - 7/98 "A Phase II Study of Amifostine in Patients with
Myelodysplastic Syndrome"

Funding source, U.S. Bioscience, Inc.

Cost of entire project \$42,000

PI: Dr. Bishop

7/1/97-6/30/98 "New and Novel Approaches to Allo- and Xeno-tolerance"

Funding source, College of Medicine and University Hospital

Cost of entire project \$15,000

PI: Dr. Sharp

Co-I: Dr. Bishop

6/1/97-5/31/98 \"A Phase II/III, Randomized, Double-Blind,
Placebo-Controlled Trial of Recombinant Human Granulocyte-Macrophage
Colony-Stimulating (rhu GM-CSF) used to prevent invasive fungal
infections in patients with graft versus host disease.\"

Funding source, Immunex

Costs of entire project \$56,000

PI: Dr. Bishop

1/1/97-6/30/98 \"A prospective multi-center observational study to
evaluate the adverse events and clinical outcomes associated with the
use of GM-CSF and G-CSF\"

Funding source, University Health Consortium

Costs of entire project \$6,541

PI: Dr. Bishop

1/1/97-12/31/97 \"Prospective evaluation of acute graft-versus-host
disease in patients undergoing allogeneic blood stem cell
transplantation.\"

Funding source, UNMC Outcomes Research Grant

Cost of entire project \$49,977

PI: Dr. Bishop

7/1/96-6/30/98 \"Anti-tumor therapeutic potential of umbilical cord
blood.\" Funding source, Elsa U. Pardee Foundation.

Cost of entire project \$131,637

PI: Dr. Joshi

Co-I: Dr. Bishop

01/01/96-12/31/98 \"A comparison of granulocyte colony stimulating
(G-CSF) versus placebo following transplantation of allogeneic
peripheral blood stem cells mobilized with G-CSF\".

Funding source, Amgen, Inc..

Cost of entire project \$204,918 (Investigator initiated)

PI: Dr. Bishop

Co-I: Dr. Joshi

10/01/94-06/30/99 \"Developmental therapeutics: Oligonucleotide therapy;
peripheral stem cell transplantation\".

Funding source, LB595, \$187,085/ \$957,839 total grant.

Co-PIs: Drs. Bishop and Vose

Co-Investigators: Drs. Joshi, Sharp, Pirruccello, Greiner, Sanger,
Crouse

11/01/93-04/30/2001 \"Therapy groups to study T-cell depletion in
unrelated donor marrow transplantation.\"

Funding source, NIH, NHLB1 HV92-24.

Cost of entire project, \$2,016,124.

PI: Dr. John Wagner, Univ. of Minnesota

Co-Investigators: Drs. Bishop, Warkentin, Gross

[Editorial Boards/Journal Review:]{.underline}

Editorial Boards:

American Society of Clinical Oncology Compendium (2005 -- 2007)

Cancer Trials -- National Cancer Institute (2000 -- 2002)

Current Stem Cell Research & Therapy (2005 -- present)

Journal of Clinical Oncology

\- Transplantation (2006 -- present)

Experimental Biology and Medicine (2006 --2009)

Ad-hoc Journal Reviews:

American Journal of Medicine

American Journal of Gastroenterology

American Journal of Hematology

American Journal of the Medical Sciences

Annals of Oncology

Biology of Blood and Marrow Transplantation

Blood

British Journal of Haematology

Bone Marrow Transplantation

Cancer Control: Journal of the Moffitt Cancer Center

Cancer Research

Cytotherapy

European Journal of Hematology

Experimental Hematology

Expert Review of Anticancer Therapy

Expert Opinion on Biologic Therapy

Haematologica

Journal of Clinical Oncology

Journal of Hematotherapy

Leukemia

Leukemia & Lymphoma

Leukemia Research

Oncology

The Oncologist

Supportive Oncology

[Honors & Awards]{.underline}:

> Veterans of Foreign Wars Academic Scholarship 1977 - 1981
>
> James Scholar of University of Illinois (Urbana-Champaign), 1978
>
> Dean's List - University of Illinois (Urbana-Champaign), 1977 - 1981
>
> Illinois General Assembly Scholarship, 1981 - 1985
>
> Senior Class President, University of Illinois College of Medicine,
> 1984 - 1985
>
> Outstanding Teaching Resident Award, 1988
>
> \- Department of Internal Medicine, Northwestern Medical School
>
> UNMC Leadership Institute 1994
>
> American Cancer Society Science Writers\' Meeting March 1994
>
> Included in The Best Doctors in America:
>
> Central Region 1996 -- 1998
>
> National 2001, 2002, 2003, 2007
>
> UNMC Top Teachers in the Department of Internal Medicine 1996, 1997,
> 1998
>
> 2003 National Institutes of Health Distinguished Clinical Teacher
> Award
>
> Board Member (honorary), Cancer Research Assistance Fund, Tulsa,
> Oklahoma (non-profit patient advocacy group promoting patient
> participation in cancer research)
>
> NIH Senior Leadership Program (Fall 2007)

[Memberships in Professional Societies]{.underline}:

> Member, American Society of Clinical Oncology
>
> Member, The American Society of Hematology
>
> Member, Leukemia Society of America (1996-1999)
>
> Board Member, Nebraska Chapter of Leukemia Society of America
> (1997-1999)
>
> Member, American Society for Blood and Marrow Transplantation (ASBMT)
>
> Fellow, American College of Physicians
>
> Member, European Society for Cancer Immunology and Immunotherapy

[Committee Assignments/Invited Participation in National/International
Meetings:]{.underline}

> Member, International Bone Marrow Transplant Registry (IBMTR)
>
> Secretary-Treasurer, Executive Committee (2004-2006)
>
> Acute Leukemia Committee (working committee)
>
> Chronic Leukemia Committee (working committee)
>
> Lymphoma Committee (working committee)
>
> Session Moderator -- GVL/GVHD and Cell Processing, 2007 Tandem
> Transplant Meeting
>
> Member, American Society of Clinical Oncology
>
> Member, ASCO OnLine Committee (1996-2000)
>
> Member, ASCO Intellectual Properties Task Force (1999-2001)
>
> Member, ASCO Sponsorship Committee (2000-2002)
>
> Member, ASCO Scientific Program Committee -- Leukemia, Lymphoma &
> Transplantation (2003-2005)
>
> Session Moderator -- Multiple Myeloma, 2004 Annual Meeting
>
> Member, Cancer Education Committee -- Compendium Editorial Board
> Subcommittee (2005-present)
>
> Member, American Society of Hematology
>
> Session moderator - Myeloproliferative Disorders, 2007 Annual Meeting
>
> Liason, Governmental Affairs Committee (NCI Director appointment;
> 2007-present)
>
> Member, Cancer and Leukemia Group B (CALGB)
>
> Member, Core member - Bone Marrow Transplant Committee (1997-1999;
> 2002-present)
>
> Member, Core member - Leukemia committee (1997-1999)
>
> Board Member, Nebraska Chapter of Leukemia Society of America
> (1995-1999)
>
> Member, American Society for Blood and Marrow Transplantation (ABMTR)
>
> Member, Leukemia Working Committee of the ABMTR
>
> Chairman, Nominations Committee (2000 -- 2003)
>
> NCCN - Practice Guidelines and Outcomes Data in Oncology Committee
> (1998-1999)
>
> Organizing Committee and Session Moderator, First International
> Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's
> Lymphoma, April 10-12, 2003, New York, New York
>
> Invited participant, NIH Workshop on Allogeneic Hematopoietic Stem
> Cell Transplantation for Auto-immune Diseases, March 12-13, 2005,
> Bethesda, MD
>
> Invited participant, Second Allogeneic Transplantation in Solid
> Tumors, October 7-8, 2005, Stresa, Italy
>
> Member, Data and Safety and Monitoring Board, Blood and Marrow
> Transplant Clinical Trials Network (2006 - present)
>
> Vice-chair (2007- present)
>
> Organizing Committee and Session Moderator, Second International
> Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's
> Lymphoma, May 18-20, 2006, New York, New York

[NCI/NIH/HHS Assignments:]{.underline}

> Member, NIH Clinical Center Chemotherapy Errors Prevention Task Force
> (2000-2001)
>
> Member, NIH Operational Review of the Clinical Center Nutrition
> Department (2002)
>
> Member, NCI Intramural Advisory Board (2000 -- 2002)
>
> Member, NIH Clinical Center Cost-Management Task Force #1
> (2001-present)
>
> Clinical Investigators Committee, MOCRU, National Cancer Institute
> (1999- present)
>
> Review of Transplantation indications for the Federal Employees Health
> Benefits Program, Office of Insurance Programs (2000, 2001, 2002,
> 2004, 2006)
>
> Intramural Advisory Board, National Cancer Institute (2000 -- 2002)
>
> NIH Clinical Center Chemotherapy-Related Error Prevention Task Force
> (2000)
>
> Chairman, Medical Oncology Clinical Research Unit Chief Search
> Committee (2001)
>
> Chairman, NCI Patient Outreach and Accrual Committee (2002 -- 2005)
>
> Member, NIH Hematopoietic Stem Cell Transplantation Interest Group
> (2002 -- present)
>
> Reviewer, NCI Medical Oncology Clinical Research Unit Protocol Review
> Committee (2003 -- 2005)
>
> Member, NIH Blood and Marrow Transplant Consortium (2003 -- present)
>
> Member, NCI CCR Immunology Faculty (2003-2005)
>
> Member, 3NE Partners Group (2004 -- present)
>
> Consultant, Oncologic Drug Advisory Committee, FDA -- May 3, 2004
>
> Member, Edmond J. Safra Family Lodge Operations Committee (2004--2005)
>
> Chairman, LTIB Senior Clinician Search Committee (2005)
>
> Member, NCI CCR MOB Branch Chief Search Committee (2005-2006)
>
> Member, Advisory Group for Patient Recruitment Project (2004-2006)
>
> Chairman, Medical Oncology Clinic Committee (2006-present)
>
> Member, NIH Clinical Center Operational Review of Department of
> Transfusion Medicine (2007-present)
>
> Chairman, Search Committee for NCI CCR MOB for Tenure-Track Position
> in Breast Cancer Research (2007- 2008)
>
> Member, NCI CCR Grand Rounds Planning Committee for 2007-2008 (2007)
>
> Reviewer, NCI Clinical Investigator Development Program (2008)
>
> Chairman, Search Committee for Staff Scientist in the Laboratory of
> Tumor Immunology and Biology, NCI CCR
>
> Member, NCI Center for Cancer Research Advisory Board (2008-present)

[Mentoring:]{.underline}

Fellow Training:

1994-1995 Salvador Martin-Algarra, M.D.

Senior Fellow in Bone Marrow Transplantation

University of Nebraska Medical Center

> Current position: Director, Department of Oncology University of
> Navarra, Pamplona, Spain

1994 -1996 Steven Z. Pavletic, M.D.

Fellow in Oncology/Hematology

University of Nebraska Medical Center

> Current position: Head, Autoimmune Diseases and Chronic Graft-
> versus-Host Disease Unit, Experimental Transplantation and Immunology
> Branch, National, Cancer Institute/NIH, Bethesda, MD

2002-2005 Robert M. Dean, M.D.

Fellow in Medical Oncology

National Cancer Institute

Current position: Assistant Professor of Medicine

Cleveland Clinic, Cleveland, OH

2004 - 2007 Nancy M. Hardy, M.D.

Senior Fellow in Medical Oncology

National Cancer Institute

> Current position: Staff Clinical Scientist, Experimental
> Transplantation and Immunology Branch, National Cancer Institute/NIH,
> Bethesda, MD

2006 -- 2007 Seth Pollack, M.D.

Resident, Internal Medicine

George Washington University Resident (clinical research project)

> Current position: Fellowship in Hematology/Oncology, University of
> Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

Graduate Education Faculty Committees:

1995-1996 Jack Lionberger M.D., Ph.D.

Member, Graduate Faculty Committee (University of Nebraska Medical
Center)

1997-1998 Erin Willis, Ph.D.

Mentor and member, Graduate Faculty Committee (University of Nebraska
Medical Center)

2003 -- 2005 Michael Boyiadzis, M.D.

Mentor (clinical) and member, Graduate Faculty Committee for NIH- Duke
Training Program in Clinical Research

[NIH Teaching Activities]{.underline}:

1999 -- present Attending, inpatient Hematopoietic Stem Cell
Transplantation Service (2 -- 3 months per year).

1999 -- present Attending, Medical Oncology Clinic (2 days per week).

1999 -- present Specialty lecture, "Acute Myelogenous Leukemia" for
NHLBI/NCI Hematology Lecture Series (once per year).

1999 -- 2000 Specialty lecture, \"Autologous Stem Cell Transplantation\"
for NHLBI/NCI lecture series (once per year).

1999 -- 2003 Specialty lecture, "Alternative Donors in Hematopoietic
Stem Cell transplantation" for NHLBI/NCI Hematology Lecture Series (once
per year).

1999 -- present Medical Oncology Fellows Journal Club (once per year).

2001 -- 2002 Specialty lecture to Medical Oncology Fellows on
"Monoclonal Antibodies", (two per year).

2001 -- present Specialty lecture to Medical Oncology Fellows on "Role
Stem Cell Transplantation for Breast Cancer", (two per year).

2003 Specialty lecture, "Bone Marrow Transplantation" for NCI CCR
Translational Research in Clinical Oncology.

2006 -- present Specialty lecture to Medical Oncology, "Overview of HLA
and Allogeneic Donor Types, Sources, and Selection" (8 -- 10 per year).

[Extramural Teaching Activities]{.underline}:

Extramural Lectures in Team-Taught Courses (University of Nebraska
Medical Center):

11/09/95 Advanced Hematology Course - \"Myelodysplastic Syndrome"

11/13/95 Transplantation -- Allogeneic

1/04/96 Winter Workshop III preceptor for students from Chadron and
Wayne State College

3/28/95 & 3/29/95 Family Practice Review - \"Evaluation of Anemia\"

4/24/96 & 5/4/95 Family Practice Review - \"Evaluation of Anemia\"

4/15/97 & 4/3/98 Family Practice Review - "Evaluation of Anemia"

Residency Related Teaching Activities (University of Nebraska Medical
Center)

1996 Lecture for Histocompatibility Study Group

1995, 1996 Annual Internal Medicine Resident Noon Conferences \"Acute
and Chronic Leukemias\" 1995 & 1996

1995 -- 1999 Core Lectures in Oncology/Hematology - Resident Lectures
(1.0 hours) given on a semi-monthly basis:

\"Principles of Chemotherapy\"

\"Principles of Bone Marrow Transplantation\"

\"Acute Leukemia\"

\"Stem Cells\"

[Grant Review:]{.underline}

> NOT-AI-04-044 Biodefense Countermeasure Development: Project
> Bioshield, HHS/NIH/NIAID. (November 2004)
>
> Grant Application Review Panel for the FDA Office of Orphan Products
> Development, (March 2005)
>
> NIH Director's New Innovator Award ( July 2007)
>
> ZRG1 Onc-B, Cancer and Immunology, Center for Scientific Review, NIH
> (October 2007)

[Community Service:]{.underline}

> Board Member, Nebraska Chapter of Leukemia Society of America,
>
> National representative, Leukemia Society of America (1996-1999)
>
> Scientific Advisor, Men Against Breast Cancer (1999-2002)
>
> Faculty, National Breast Cancer Coalition, 1999
>
> Board Member, Medical Advisory Committee, National Capitol Area of The
> Leukemia & Lymphoma Society (2004 -- 2007)

-   Leukemia & Lymphoma Society Patient Education Program -- "Transplant
    Options for Patients with Multiple Myeloma", January 18, 2005,
    Fairfax, Virginia

-   Leukemia & Lymphoma Society Patient Education Program -
    "Non-Hodgkin's Lymphoma", October 17, 2005, Fairfax, Virginia

> Script consultant (through NCI Office of Communication) to The Norman
> Lear Center\
> USC Annenberg School for Communication (2004 -- present)

[Extramural Faculty Activities]{.underline}:

> National Marrow Donor Program, Donation Center Director, University of
> Nebraska Medical Center (1994-1999)
>
> Institutional Director, International Bone Marrow Transplantation
> Registry, University of Nebraska Medical Center (1992 -- 1999)
>
> Director, Leukemia Program and Allogeneic Bone Marrow Transplantation,
> University of Nebraska Medical Center (1992-1999)

[NIH Protocols (1999 -- present)]{.underline}:

> CC 96-C-0104: A Pilot Study of Paclitaxel/Cyclophosphamide and
> High-Dose Melphalan/Etoposide with Autologous Progenitor Cell
> Transplantation for the Treatment of Inflammatory Breast Cancer.
>
> Role: Associate Investigator (patient care)
>
> Study open date: 06/20/97; Study accrual to date = 110
>
> CC 99-C-0143 (NCI Protocol \# 3491): Pilot Study of Donor Th2 Cells
> for the Prevention of Graft-Versus-Host Disease in the Setting of
> Non-myeloablative, HLA-matched Allogeneic Peripheral Blood Stem Cell
> Transplantation.
>
> Role: Study Chairperson
>
> Study open date: 07/12/99; Study closure date: 03/05/03; Study accrual
> = 110
>
> CC 00-C-0119: Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic
> Blood Stem Cell Transplantation Using an Immunoablative Conditioning
> Regimen in Metastatic Breast Cancer.
>
> Role: Principal Investigator.
>
> Study open date: 04/18/00; Study closure date: 09/20/04; Study accrual
> = 52
>
> CC 00-C-0078: Collection of Blood, Bone Marrow, Tumor, or Tissue
> Samples from Patients with Cancer.
>
> Role: Associate investigator.
>
> CC 00- C-0121: A Phase I Investigation of IL-12/Pulse IL-2 in Adults
> with Advanced Solid Tumors.
>
> Role: Associate investigator.
>
> CC 00-C-0201 (NCI Protocol #1029): Active Immunization of Sibling Stem
> Cell Transplant Donors Against Purified Myeloma Protein of the Stem
> Cell Recipient with Multiple Myeloma in the Setting of
> Non-myeloablative, HLA-matched Allogeneic Peripheral Blood Stem Cell
> Transplantation.
>
> Role: Principal Investigator.
>
> Study open date: 06/08/00; Study accrual to date = 21
>
> CC 00-C-0206 (CTEP Protocol NCI \# 213): Phase I Study of Yttrium
> 90-labeled Monoclonal Antibody B3 with Autologous Stem Cell Support
> for Metastatic Breast Cancer
>
> Role: Principal Investigator
>
> Study open date: 04/21/00; Study closure date: 09/08/03; Study accrual
> number = 2
>
> CC 01-C-0125: Pilot Study of Non-myeloablative, HLA-matched Allogeneic
> Stem Cell Transplantation for Pediatric Hematopoietic Malignancies.
>
> Role: Clinical Chairperson
>
> Study open date: 03/09/01; Study accrual to date = 22
>
> CC 01-C-0144: Surveillance of Invasive Fungal Infections in Bone
> Marrow /Stem Cell and Solid Organ Transplantation Recipients and Other
> Immunocompromised Patients: A Prospective Study.
>
> Role: Associate Investigator (protocol development, patient
> recruitment and care)
>
> Study open date: 03/25/01; Study accrual to date = 64
>
> CC 02-C-0259: Pilot Study of Allogeneic Blood Stem Cell
> Transplantation in Patients with High-Risk and Recurrent Pediatric
> Sarcomas.
>
> Role: Associate Investigator (protocol development)
>
> Study open date: 07/01/02; Study accrual to date = 42
>
> CC 03-C0-0077: A Pilot Study of EPOCH-F/R Induction Chemotherapy and
> Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem
> Cell Transplantation for Refractory or Relapsed Hematologic
> Malignancies, with Cyclosporine & Methotrexate for Graft-Versus-Host
> Disease Prophylaxis.
>
> Role: Principal Investigator
>
> Study open date: 12/30/02; Study closure date: 11/15/04; Study accrual
> = 62
>
> CC 03-C-0040: A Phase I-II Study of Tumor Vaccine Following
> Chemotherapy in Patients with Previously Untreated Metastatic Breast
> Cancer; Vaccine-Induced Bias of T-Cell Repertoire Reconstitution after
> T-Cell Re-Infusion.
>
> Role: Associate Investigator (protocol development; patient care)
>
> Study open date: 08/26/02; Study accrual to date = 22
>
> CC 03-C-0152: A Phase 1 Study of Subcutaneous "CYT 99 007"
> (Interleukin 7) in Patients with Refractory Non-Hematologic
> Malignancy.
>
> Role: Associate Investigator (protocol development; patient care)
>
> Study open date: 03/27/03; Study accrual to date = 21
>
> CC 03-C-0205: A Phase I-II Safety, Tolerability and Pharmacokinetic
> Study of Ravuconazole for Prophylaxis of Invasive Fungal Infections in
> Patients Undergoing a Non-Myeloablative Allogeneic Hematopoietic Stem
> Cell Transplant.
>
> Role: Associate Investigator (protocol development, patient accrual,
> patient care)
>
> Study open date: 05/23/03; Study termination date: 09/07/04; Study
> accrual = 27
>
> CC 03-I-0025: Treatment of Chronic Graft Versus Host Disease with
> Extracorporeal Photopheresis.
>
> Role: Associate Investigator (protocol development, patient accrual;
> patient care)
>
> Study open date: 11/14/02; Study accrual to date = 13
>
> 03-CC-0028: Exploring the Relationship Between Personality and Coping
> Styles in Bone Marrow Transplant Candidates.
>
> Role: Associate Investigator (protocol development, patient accrual)
>
> Study open date: 10/17/02; Study termination date: 08/29/05; Study
> accrual = 53
>
> CC 04-C-0116: T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell
> Transplantation from Haploidentical Related Donors for Hematologic
> Malignancies (HAPLO Part A).
>
> Role: Principal Investigator.
>
> Study open date: Study accrual to date = 2
>
> CC 04-C-0055: Randomized Study of Sirolimus (Rapamycin) Generated
> Donor Th2 Cells and In Vivo Sirolimus for GVHD Prevention after
> Allogeneic HSCT for Hematologic Malignancy.
>
> Role: Protocol Chairperson
>
> Study open date: 12/01/03; Study accrual to date = 68
>
> CC 04-C-0095: A Pilot Study of Intensified Lymphodepletion Followed by
> Autologous Hematopoietic Stem Cell Transplantation in Patients with
> Severe Systemic Lupus Erythematosus.
>
> Role: Associate Investigator (protocol development; patient care)
>
> Study open date: 12/15/03; Study accrual to date = 8
>
> CC 04-C-0102: Hematologic Malignancy Biology Study.
>
> Role: Associate Investigator (protocol development)
>
> Study open date: 01/20/04; Study accrual to date = 21
>
> CC 04-C-0131: Allogeneic Breast Protocol 2: Phase I Trial of T cell
> Exchange with Th2/Tc2 Cells for Allogeneic Stem Cell Transplantation
> after Reduced Intensity Conditioning for Metastatic Breast Cancer.
>
> Role: Principal Investigator.
>
> Study open date: 01/20/04; Study accrual to date = 3
>
> CC 04-C-0277: Phase II Study in Metastatic Renal Cell Cancer using
> Cultured, Tumor-Reactive Lymphocytes and Interleukin-2.
>
> Role: Associate Investigator (patient care)
>
> Study open date: 01/28/04; Study accrual to date = 2
>
> CC 04-C-0281: Prospective Assessment of Clinical and Biological
> Factors Determining Outcomes in Patients with Chronic
> Graft-Versus-Host Disease.
>
> Role: Associate Investigator (protocol development, patient accrual,
> patient care)
>
> Study open date: 08/16/04; Study accrual to date = 41
>
> CC 04-C-0288: Treatment of Patients with Metastatic Melanoma using a
> Transplant of Autologous Lymphocytes Reactive with Tumor Following a
> Myeloablative Lymphocyte Depleting Regimen of Chemotherapy, Total Body
> Irradiation, and Reconstitution with CD34+ Cells.
>
> Role: Associate Investigator (protocol development, patient care)
>
> Study open date: 08/16/04; Study accrual to date = 34
>
> CC 05-C-9980: Adoptive Immunotherapy With Costimulated Tumor-Derived T
> Cells After Allogeneic Hematopoietic Stem Cell Transplantation.
>
> Role: Principal Investigator
>
> Study termination date: 09/30/05; Single patient trial approved by FDA
>
> CC 04-C-0288D: Treatment of Patients with Metastatic Melanoma Using a
> Transplant of Autologous Lymphocytes Reactive with Tumor Following a
> Myeloablative Lymphocyte Depleting Regimen of Chemotherapy, Total body
> Irradiation and Reconstitution with CD34+ Cells. (submitted to IRB)
>
> Role: Associate Investigator (protocol development, patient care)
>
> Study open date: Study accrual to date =
>
> CC 06-C-0136: Phase II Study Using a Myeloablative Lymphocyte
> Depleting Regimen of Chemotherapy and Intensive Total Body Irradiation
> Followed by Infusion of Tumor Reactive Lymphocytes and Reconstitution
> with CD34+ Stem Cells in Metastatic Melanoma.
>
> Role: Associate Investigator (protocol development, patient care)
>
> Study open date: 03/16/06; Study accrual to date =
>
> CC 07-C-0064: Adoptive Cell Therapy for B-Cell Malignancies After
> Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated,
> Tumor-Derived Lymphocytes.
>
> Role: Principal Investigator.
>
> Study open date: 01/12/07; Study accrual to date = 2
>
> CC 07-C-0195: Pilot Trial of Targeted Immune-Depleting Chemotherapy
> and Reduced-Intensity Allogeneic Hematopoietic Stem Cell
> Transplantation Using HLA-matched Unrelated Donors and Utilizing Two
> Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of
> Leukemias, Lymphomas, and Pre-malignant Blood Disorders
>
> Role: Principal Investigator.
>
> Study open date: 09/30/07; Study accrual to date = 3
>
> CC 08-C-XXXX: A Randomized Double-Blind Pilot Study of Pirfenidone and
> Pentostatin versus Placebo and Pentostatin in Children and Adults with
> Sclerotic Skin Changes or Bronchiolitis Obliterans Manifestations of
> Chronic Graft-Versus-Host Disease.
>
> Role: Associate Investigator (protocol development, patient accrual,
> patient care)
>
> (Submitted to IRB)

[Selected Invited Presentations (since 1999):]{.underline}

1\. "Graft-vs-Host Disease", Temple University Hospital, Philadelphia,
Pennsylvania, February 11, 1999.

2\. "Clinical Results of Allogeneic Blood Stem Cell Transplantation at
UNMC", University of Nebraska Medical Center Allogeneic Stem Cell
Conference, Omaha, Nebraska, March 19, 1999.

3\. "Graft-vs-Host Disease: Diagnosis and Treatment", Medical Grand
Rounds at Loyola University - Stritch School of Medicine, Chicago,
Illinois, March 30, 1999.

4\. "Allogeneic Stem Cell Transplantation", University of Nebraska
Medical Center Internal Medicine Grand Rounds, Omaha, Nebraska, April 9,
1999.

5\. "Critical Issues in Allogeneic Stem Cell Transplantation", 7th
International Symposium - Recent Advances in Hematopoietic Stem Cell
Transplantation - University of California (UCSD), San Diego,
California, May 6 - 8, 1999.

6\. "The Role of Clinical Trials in Blood and Marrow Transplantation",
The Evolving Role of Blood and Marrow Transplantation -- United Resource
Networks, Naples, Florida, January 24, 2000

7\. "Lymphomas -- What's New?" -- Update on Hematologic Malignancies and
Multiple Myeloma -- The Arkansas Cancer Research Center at the
University of Arkansas for Medical Sciences, Little Rock, AR, March
17-18, 2000

8\. \"Overview of Chronic Graft-versus-Host Disease\". -- Emerging
Strategies in the Treatment of Chronic Graft-versus-Host Disease, 2001
Tandem Transplant Meetings, Keystone, Colorado, February 26, 2001

9\. "Non-myeloablative Allogeneic Stem Cell Transplantation", Moffitt
Cancer Center Grand Rounds, H. Lee Moffitt Cancer Center & Research
Institute, Tampa, FL, March 23, 2001

10\. "Hematologic Reconstitution After Allogeneic PBPC Transplantation",
The Evolving World of Cellular Support -- 27^th^ Annual Meeting European
Group for Blood and Marrow Transplantation, Maastricht, The Netherlands,
March 25, 2001

11\. \"Hematopoietic Stem Cell Transplantation for Metastatic Breast
Cancer\", 21^st^ Annual Symposium: Immunohematology and Blood
Transfusion, Bethesda, MD, September 26, 2002

12\. \"Non-myeloablative Allogeneic stem Cell Transplantation for
Non-Hodgkin\'s Lymphoma\", Innovations in Lymphoma Treatment -- Lymphoma
Research Foundation, Chicago, IL, June 15, 2002

13\. \"Submyeloablative Allogeneic Stem Cell Transplantation in Breast
Cancer\", Future of Breast Cancer: An International Breast Cancer
Symposium, Paradise Islands, the Bahamas, July 31-August 3, 2002

14\. \"Experimental Model of Transplantation\", Cleveland Clinic Cancer
Center grand Rounds, Cleveland, OH, November 15, 2002

15\. "Blood and Marrow Transplantation for Low Grade and Mantle Cell
Lymphomas", United Resource Networks 5^th^ Annual Evolving Science of
Blood/Marrow Transplantation Conference, New Orleans, LA, March 12-14,
2003

16\. "Reduced Intensity Allogeneic hematopoietic Stem Cell
Transplantation", 5th NCI/CCR Annual Symposium for Practicing
Physicians, Bethesda, MD, May 10, 2003

17\. "Non-myeloablative Allogeneic Hematopoietic Stem Cell
Transplantation for Solid Tumors", Educational Session, 2003 Annual
Meeting of American Society of Clinical Oncology, Chicago, IL, May 31 --
June 4, 2003

18\. "Adoptive Immunotherapy for Malignant Disease", American Society of
Clinical Oncology Annual Meeting Educational Session, Chicago, IL, May
31 -- June 4, 2003

19\. "'But Doctor, What Have I Got to Lose....', A Research Clinician's
Perspective of Phase I Trials", Patient Advocate Foundation, Patient
Congress IV, Washington, DC, June 4-6, 2003

20\. "Stem Cell Transplantation: Promise in Cancer Treatments and Blood
Disorders", NIH Clinical Center 2003 Medicine for the Public Series,
Bethesda, MD, October 7, 2003

21\. "Tumor Lysis Syndrome", Washington Hospital Center, Washington,
D.C., February 27, 2004

22\. \"Allogeneic Hematopoietic Stem Cell Transplantation for
Non-Hodgkin\'s Lymphoma\", Georgetown University Hospital BMT
Conference, Georgetown University Hospital, Washington, D.C., April 15,
2004

23\. "Allogeneic T Cells as Adoptive Immunotherapy for Metastatic breast
Cancer", First Annual John Laws Decker Memorial Lecture, NIH Clinical
Center, National Institutes of Health, Bethesda, MD, June 2, 2004

24\. "Hematopoietic Stem Cell Transplantation", The George Washing
University Medical Center's Hematology/Medical Oncology Board Review
Course, Alexandria, Virginia, October 6 - 13, 2004

25\. "Allogeneic T Cells as Adoptive Immunotherapy for Metastatic Breast
Cancer", 8^th^ Annual Meeting of the Regional Cancer Center Consortium
for the Biological Therapy of Cancer, Hershey, PA, February 24-26, 2005

26\. "Factors Affecting Full Donor Engraftment of Allogeneic
Hematopoietic Stem Cells after Reduced-Intensity Conditioning", NIH
Workshop for Hematopoietic Cell Transplantation for Autoimmune Disease,
Bethesda, MD, March 13, 2005

27\. "Tumor Antigen Immunization of Human Allotransplant Donors in
Myeloma", 10^th^ International Myeloma Workshop, Sydney, Australia,
April 10-14, 2005

28\. "Hematopoietic Stem Cell Transplantation for Non-Hodgkin's
Lymphoma", Hematology-Oncology Conference, Howard University Medical
Center, Washington, D.C., August 26, 2005

29\. "Hematopoietic Stem Cell Transplantation", The George Washing
University Medical Center's Hematology/Medical Oncology Board Review
Course, Alexandria, Virginia, September 21 -- 28, 2005

30\. "Allogeneic T Cells as Adoptive Immunotherapy for Metastatic Breast
Cancer", 2^nd^ ASCT Meeting -- Allogeneic Transplantation in Solid
Tumors, Stresa-Lago Maggiore, Italy, October 7-8, 2005

31\. "Immunotherapy", Mount Vernon Hospital grand Rounds, Mount Vernon,
Virginia, October 25, 2005

32\. \"Treatment of Lymphoma\", Doctors Community Hospital Grand Rounds,
Lanham, Maryland, February 9, 2006

33\. "Adoptive Cellular Therapy", Cardeza Foundation for Hematologic
Research, Thomas Jefferson University, Philadelphia, PA, February 21,
2006

34\. "Hematopoietic Stem Cell Transplantation for Hematologic
Malignancies", Hematology-Oncology Conference, Walter Reed Army Medical
Center, Washington, D.C., March 8, 2005

35\. "Increasing Indications for Allogeneic Hematopoietic Stem
Transplantation", Educational Session, 42^nd^ Annual Meeting of the
American Society of Clinical Oncology, Atlanta, Georgia, June 5, 2006

36\. "Diagnostic & Therapeutic Options for Non-Hodgkin's Lymphoma", Nova
Fairfax Hospital, Fairfax, Virginia, September 19, 2006

37\. "T-cell Depletion and Host Immune Reconstitution after
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation",
2nd Annual Frontiers of Clinical Investigation: Bench to Bedside
Symposium (co-sponsored by Nature Medicine and the UCSD Clinical
Investigation Institute), La Jolla, California, October 5-7, 2006

38\. "Targeted Therapies -- Vaccines, Stem Cell Transplantation and
Novel Approaches", Oncology Update 2006: Treatment Advances for breast
Lung and Colon Cancer, Saint Agnes Medical Center, Fresno, California,
October 7, 2006 (Keynote speaker).

39\. "Hematopoietic Stem Cell Transplantation", The George Washing
University Medical Center's Hematology/Medical Oncology Board Review
Course, Arlington, Virginia, October 4-8, 2006

40\. "Hematopoietic Stem Cell Transplantation for Cutaneous T-cell
Lymphoma", NCI CTCL Interest Group, Bethesda, MD, November 20, 2006

41\. "Non-Myeloablative Hematopoietic Stem Cell Transplantation\",
International Society for Cutaneous Lymphoma, Washington, DC, February
1, 2007

42\. "The Role of Stem Cell Transplantation in Lymphoma Therapy\",
Washington Hospital Center, Washington, DC, March 23, 2007

43\. "Allogeneic Hematopoietic Stem Cell Transplantation for
Non-Hodgkin's Lymphoma", M.D. Anderson Cancer Center, Houston, TX, April
18, 2007

44\. "Organizational Structure of Medical Oncology in the United
States", Clinical Oncology in Croatia - Strategic planning and Beyond,
Zagreb, Croatia, May 11-13, 2007

45\. "Hematopoietic Stem Cell Transplantation", The George Washing
University Medical Center's Hematology/Medical Oncology Board Review
Course, Washington, DC, September 29 -- October 3, 2007

[Publications]{.underline}:

1\. Messmore HL, **Bishop MR**, Wehrmacher WH. Acute venous thrombosis:
Therapeutic choices for superficial and deep veins. Postgraduate
Medicine 89:73-77, 1991 (invited review).

2\. Stiff PJ, Schulz WC, **Bishop MR**, Marks L. Anti-CD33 monoclonal
antibody and etoposide/cytosine arabinoside combinations for the ex vivo
purification bone marrow in acute non-lymphocytic leukemia. Blood
77:355-362, 1991.

3\. **Bishop MR**, Bierman PJ, Vose JM, and Armitage JO. The Role of
High-Dose Therapy With Hematopoietic Stem Cell Rescue in Low-Grade
Non-Hodgkin\'s Lymphoma. Annals of Oncology 4(suppl 1):1-6, 1993.

4\. **Bishop, MR**. Discovery\--And Implications\--Of a Single Human
Bone Marrow Stem Cell. Oncology Bulletin 16:2, 1993.

5\. Bayever E, Iversen PL, **Bishop MR**, Sharp JG, Tewary HK, Arneson
MA, Pirruccello SJ, Ruddon RW, Kessinger A, Zon G and Armitage JO.
Systemic administration of a phosphorothioate oligonucleotide with a
sequence complementary to p53 for acute myelogenous leukemia and
myelodysplastic syndrome: Initial results of a phase I trial. Antisense
Research and Development, 3:383-390, 1993.

6\. Kessinger A, Vose JM, Bierman PJ, **Bishop MR**, Armitage JO.
Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients.
Journal of Hematotherapy 2:361-2, 1993.

7\. **Bishop MR**, Anderson JR, Jackson JD, Bierman PJ, Reed EC, Vose
JV, Armitage JO, Warkentin PI, Kessinger A. High-dose therapy and
peripheral blood progenitor cell transplantation: Effects of recombinant
human granulocyte-macrophage colony-stimulating factor on the autograft.
Blood 83:610-616, 1994.

8\. Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger D, Chan WC,
**Bishop MR**, Armitage JO. Comparison of front-line chemotherapy for
aggressive non-Hodgkin\'s lymphoma using the CAP-BOP regimens. Semin
Hematol 31(Suppl 3):4-8, 1994.

9\. Armitage JO, Vose JM, Bierman PJ, **Bishop MR**. Salvage therapy for
patients with lymphoma. Seminars in Oncology, 21(Suppl 7):82-5, 1994.

10\. **Bishop MR**, Bierman PJ, Vose JM, and Armitage JO. Non-Hodgkin\'s
Lymphoma and Autologous Stem Cell Transplantation: A Critical Review.
Revisions en Cáncer, 8:158-164, 1994.

11\. **Bishop MR**, Warkentin PI, Jackson JD, Bayever E, Iversen PL,
Whalen VI, Lastovica J, Haines K, Kessinger A. Antisense oligonucleotide
OL (1)P53 for in vitro purging of autologous bone marrow in acute
myelogenous leukemia. Prog Clin Biol Res 389:183-7, 1994.

12\. Jackson JD, Letheby B, O\'Kane Murphy B, Costas P, Wang PN,
**Bishop MR**, Kessinger A, Warkentin PI. Kinetics of low and high dose
granulocyte/macrophage colony stimulating factor mobilization of
peripheral blood stem cells. Prog Clin Biol Res 389:471-7, 1994.

13\. Kessinger A, Vose JM, Bierman PJ, **Bishop MR**, and Armitage JO.
Peripheral blood stem cell transplantation in malignant lymphomas. Hem
Onc Annals 3:47-52, 1994.

14\. Kessinger A, Armitage J, Bierman P, **Bishop M**, Joshi S, Reed E,
Sharp G, Talmadge J, Vose J. Clinical outcome of peripheral blood stem
cell support. Medical Oncology 11:43-46, 1994.

15\. Darrington DL, Vose JM, Anderson JR, Bierman PJ, **Bishop MR**,
Chan WC, Reed EC, Sanger WG, Tarantolo SR, Weisenburger DD, Morris ME,
Kessinger A, Armitage JO. Incidence and Characterization of Secondary
Myelodysplastic Syndrome and Acute Myelogenous Leukemia Following
High-Dose Chemoradiotherapy and Autologous Stem Cell Transplantation for
Lymphoid Malignancies. J Clin Oncol 12:2527-34, 1994.

16\. **Bishop MR**, Armitage JO. Cytokine therapy in bone marrow
transplantation. Advances in the Biosciences 94:15-20, 1994.

17\. Armitage JO, Bierman PJ, Vose JM, **Bishop MR**, Kessinger MA.
Autologous bone marrow transplantation for Hodgkin\'s disease. J
Hematotherapy 4:61-2, 1995.

18\. Kessinger A, **Bishop MR**, Anderson J, Armitage JO, Bierman PJ,
Reed E, Tarantolo S, Tempero M, Vose JM, and Warkentin PI. A comparison
of subcutaneous and intravenous administration of rhGM-CSF for
peripheral blood stem cell mobilization. J Hematotherapy. 4:81-4, 1995.

19\. Kessinger A, **Bishop MR**, Jackson JD, O\'Kane-Murphy B, Vose JM,
Bierman PJ, Reed EC, Warkentin PI, Armitage JO, Sharp JG. Erythropoietin
for mobilization of circulating progenitor cells in patients with
previously treated relapsed malignancies. Exp Hematol 23:609-12, 1995.

20\. Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A,
Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ, Whalen VL, **Bishop
MR**. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human
chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Leukemia Lymphoma 20:67-76, 1995.

21\. Martin-Algarra S, **Bishop MR**, Tarantolo S, Cowles MK, Reed E,
Anderson JR, Vose JM, Bierman P, Armitage JO, and Kessinger A.
Hematopoietic growth factors after HLA-identical allogeneic bone marrow
transplantation in patients treated with methotrexate-containing
graft-vs.-host disease prophylaxis. Experimental Hematology 23:1503-08,
1995.

22\. Sharp JG, **Bishop MR**, Chan WC, Greiner T, Joshi SS, Kessinger A,
Reed E, Sanger W, Tarantolo S, Traystman M, et-al. Detection of minimal
residual disease in hematopoietic tissues. Ann New York Acad Sci
770:242-61, 1995.

23\. Joshi SS, Wu AG, Verbik DJ, Algarra SM, **Bishop MR**, Pirruccello
SJ, Iversen PL, Jackson JD, Kessinger MA, Sharp JG. Oligonucleotides
complementary to c-myb messenger RNA inhibit growth and induce apoptosis
in human Burkitt Lymphoma cells. International Journal of Oncology
8:815-20, 1996.

24\. **Bishop MR**, Iversen PL, Bayever E, Sharp JG, Greiner TC, Ruddon
R, Zon G, Spinolo J, Arneson M, Armitage JO, and Kessinger A. Phase I
trial of an antisense oligonucleotide OL(1)p53 in hematologic
malignancies. J Clin Onc 14:1320-6, 1996.

25\. Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A, **Bishop
MR**, Armitage JO. High-dose chemotherapy followed by autologous
hematopoietic rescue for Hodgkin\'s disease patients following first
relapse after chemotherapy. Ann Oncology 7:151-156, 1996.

26\. Pavletic ZS, **Bishop MR**, Bierman PJ, Armitage JO. Bone marrow
transplantation in chronic lymphocytic leukemia and lymphomas.
Biomedicine Pharmacotherapy 50:118-24, 1996.

27\. Fleming DR, Henslee-Downey PJ, Harder EJ, Romond EH, Marciniak E,
Munn RK, Messino MJ, Macdonald JS, **Bishop M**, Rayens MK, Thompson JS,
Foon KA. Allogeneic bone marrow transplantation with T cell-depleted
partially matched related donors for advanced acute lymphoblastic
leukemia in children and adults: a comparative matched cohort study.
Bone Marrow Transplant 17:917-22, 1996.

28\. Pavletic ZS, **Bishop MR**, Markopoulou K, and Wszolek ZK.
Drug-induced Parkinsonism after allogeneic bone marrow transplantation.
Bone Marrow Transplant 17:1185-7, 1996.

29\. Vose JM, Bierman PJ, Ruby E, Reed EC, **Bishop MR**, Tarantolo S,
Kessinger A, and Armitage JO. Use of continuous infusion
granulocyte-macrophage colony-stimulating factor alone or followed by
granulocyte colony-stimulating factor to enhance engraftment following
high-dose chemotherapy and autologous bone marrow transplantation for
lymphoid malignancies. Bone Marrow Transplant 17:951-6, 1996.

30\. **Bishop MR**, Jackson JD, O\'Kane-Murphy B, Schmit-Pokorny K, Vose
JM, Bierman PJ, Warkentin PI, Armitage JO, Garrison L, and Kessinger A.
Phase I trial of recombinant fusion protein PIXY321 for mobilization of
peripheral-blood cells. J Clin Oncol 14:2521-6, 1996.

31\. Bennett CL, **Bishop MR**, Gulati SC. Economic implications of high
dose chemotherapy programs with autologous stem cell support. Proc
Molecular Biol Hematopoiesis, 5:45-52, 1996.

32\. **Bishop MR**, Henslee-Downey PJ, Anderson JR, Romond EH, Marciniak
E, Yankey R, Reeves M and Thompson JS. Long-term survival in advanced
chronic myelogenous leukemia following bone marrow transplantation from
haploidentical related donors. Bone Marrow Transplant 18:747-53, 1996.

33\. O'Donnell MR, Appelbaum F, **Bishop MR**, Estey EH, Grever M,
Maslak P. NCCN Acute Leukemia Practice Guidelines. The National
Comprehensive Cancer Network. Oncology 10(11 Suppl):205-21, 1996.

34\. Bierman PJ, Vose JM, Anderson JR, **Bishop MR**, Kessinger A,
Armitage JO. High-dose therapy with autologous hematopoietic rescue for
follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-50,
1997.

35\. **Bishop MR**, Kessinger A. Blood stem cell transplantation in
non-hodgkin\'s lymphoma. Cancer Invest 15:138-42, 1997 (invited review).

36\. **Bishop MR**, Tarantolo SR, Jackson JD, Anderson JR,
Schmit-Pokorny K, Zacharias D, Pavletic ZS, Pirruccello SJ, Vose JV,
Bierman PJ, Warkentin PI, Armitage JO, Kessinger A. Allogeneic-blood
stem-cell collection following mobilization with low-dose granulocyte
colony-stimulating factor. J Clin Oncol 15:1601-07, 1997.

37\. Pavletic ZS, **Bishop MR**, Tarantolo SR, Martin-Algarra S, Bierman
PJ, Vose JM, Reed EC, Gross TJ, Kollath J, Nasrati K, Jackson JD,
Armitage JO, Kessinger A. Hematopoietic recovery after allogeneic blood
stem-cell transplantation compared with bone marrow transplantation in
patients with hematologic malignancies. J Clin Oncol 15:1608-16, 1997.

38\. **Bishop MR**. Potential use of hematopoietic stem cells after
radiation injury. Radiation Injury and the Chernobyl Catastrophe. Stem
Cells 15(suppl 2): 305-10, 1997.

39\. Benner E, **Bishop MR**, Agarwal N, Iversen P, Joshi SS.
Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in
Hematological Malignancies. J Pharmacological and Toxicological Methods
37:229-35, 1997.

40\. **Bishop MR**, Jackson JD, Tarantolo SR, O-Kane-Murphy B, Iversen
PL, Bayever E, Joshi SM, Sharp JG, Pierson JL, Warkentin PI, Armitage
JO, Kessinger A. Ex Vivo treatment of bone marrow with phosphorothioate
oligonucleotide OL(1)p53 for autologous transplantation in acute
myelogenous leukemia and myelodysplastic syndrome. J Hematotherapy
6:441-46, 1997.

41\. Rao AK, Kuszynski CA, Benner E, **Bishop MR**, Jackson JD, Iversen
PL, Joshi SS. Increased growth inhibition of human chronic myelogenous
leukemic cells by a combination of c-myb antisense oligonucleotide and
4-hydroxperoxycyclophosphamide in vitro. Int J Oncol, 11:281-287, 1997.

42\. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J,
Reed EC, Bierman PJ, Vose JM, Warkentin PI, Gross TG, Nasrati K,
Armitage JO, Kessinger A, **Bishop MR**. Lymphocyte reconstitution after
allogeneic blood stem cell transplantation for hematologic malignancies.
Bone Marrow Transplant 21:33-41, 1998.

43\. Gross TG, Hinrichs MD, Davis JR, Mitchell D, **Bishop MR**, Wagner
JE. Depletion of (EBV) infected cells in donor marrow by counterflow
elutriation. Exp Hematol 26:395-9, 1998.

44\. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO,
**Bishop MR**, Chaekal O, Gale RP, Klein JP, Lazarus HM, McCarthy PL,
Raemaekers JMM, Reiffers J, Phillips GL, Schattenberg AVMB, Verdonck LF,
Vose JM, Horowitz MM. Allogeneic Bone Marrow Transplantation For Low
Grade Lymphoma. Blood 92:1832-6, 1998.

45\. Kessinger A, Bierman PJ, Cowles MK, Anderson JR, Armitage JO,
**Bishop MR**, Vose JM. Mobilized Versus Non-Mobilized Peripheral Stem
Cell Transplantation After High Dose Therapy for Low Grade Nonhodgkin
Lymphoma. Cancer Res Ther Control, 5:113-9, 1998.

46\. Joshi SS, Babushkina-Patz NN, Verbik DJ, Gross TG, Tarantolo SR,
Kuszynski CA, Pirruccello SJ, **Bishop MR**, Kessinger A. Antitumor
activity of human umbilical cord blood cells: A comparative analysis
with peripheral blood and bone marrow cells. Int J Oncol 13:791-799,
1998.

47\. Pavletic ZS, Bierman PJ, Vose JM, **Bishop MR**, Wu CD, Pierson JL,
Kollath JP, Weisenburger DD, Kessinger A, Armitage JO. High incidence of
relapse after autologous stem-cell transplantation for B-cell chronic
lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 9:1023-6,
1998.

48\. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J,
Reed EC, Bierman PJ, Vose JM, Warkentin PI, Gross TG, Nasrati K,
Armitage JO, Kessinger A, **Bishop MR**. Lymphocyte reconstitution after
allogeneic blood stem cell transplantation for hematologic malignancies
Bone Marrow Transplant 21:33-41, 1998.

49\. Haire WD, Ruby EI, Stephens LC, Reed E, Tarantolo SR, Pavletic ZS,
Bierman PJ, **Bishop MR**, Kessinger A, Vose J, Armitage JO. A
Prospective, Randomized, Double-Blind Trial of Antithrombin III
Concentrate in the Treatment of Multiple Organ Dysfunction Syndrome
During Hematopoietic Stem Cell Transplantation. Biol Blood Marrow
Transplant 4:142-50, 1998.

50\. **Bishop MR**. The risk of secondary leukemias following autologous
stem cell transplantation. Commentary on the paper by G Lambertenghi
Deliliers et al. Cytogenetic and myelodysplasztic alterations after
autologous hemopoietic stem cell transplantations. Leukemia Res
23:281-2, 1999.

51\. Greengerg P, **Bishop MR**, Deeg J, Estey E, Erba H, Gore S, Nimer
S, O'Donnell M, Stone R, Tallman M, Bennett J. NCCN Practice Guidelines
for the Myelodysplastic Syndromes. Oncology 12:53-80, 1998.

52\. Brand RE, DiBaise JK, Quigley EMM, Gobar LS, Harmon KS, Lynch JC,
Bierman PJ, **Bishop MR**, Tarantolo SR. Gastroparesis as a cause of
nausea and vomiting after high dose chemotherapy and haemopoietic
stem-cell transplantation. Lancet 352:1985, 1998.

53\. Iwen PC, Rupp ME, **Bishop MR**, Rinaldi MG, Sutton DA, Tarantolo
S, Hinrichs SH. Disseminated Aspergillosis Caused by Aspergillus ustus
in a Patient Following Allogeneic Peripheral Stem Cell Transplantation.
J Clin Microbiol 36:3713-17, 1998.

54\. **Bishop MR**. Alternative Donor Sources in Allogeneic Stem Cell
Transplantation. Medscape Oncology 1(6), 1998. (online publication)

55\. Pavletic ZS, Bierman PJ, Vose JM, **Bishop MR**, Wu CD, Pierson JL,
Kollath JP, Weisenburger DD, Kessinger A, Armitage JO. High incidence of
relapse after autologous stem-cell transplantation for B-cell chronic
lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 9:1023-6,
1998.

56\. Freeman M, Vose J, Bennett C, Anderson J, Kessinger A, Turner K,
Pierson J, **Bishop M**, Bierman P, Armitage J. Costs of care associated
with high-dose therapy and autologous transplantation for non-Hodgkin\'s
lymphoma: results from the University of Nebraska Medical Center 1989 to
1995. Bone Marrow Transplant 24:679-84, 1999.

57\. Pirruccello SJ, Page CJ, **Bishop MR**, Letheby BA, Warkentin PI,
Jackson JD, Kessinger A. Comparison of ISHAGE Protocol CD34 Cell
Enumeration with a Lineage Negative Backgating Technique. Cytotherapy
1:279-86, 1999.

58\. Bennett C, Waters T, Stinson T, Almagor O, Pavletic Z, Tarantolo S,
**Bishop M**. Valuing clinical strategies early in development: a cost
analysis of allogeneic peripheral blood stem cell transplantation. Bone
Marrow Transplant 24:555-60, 1999.

59\. Bennett CL, **Bishop MR**, Tallman MS, Somerfield MR, Feinglass J,
Smith TJ. The association between physician reimbursement in the US and
use of hematopoietic colony stimulating factors as adjunct therapy for
older patients with acute myeloid leukemia: results from the 1997
American Society of Clinical Oncology survey. Health Services Research
Committee of the American Society of Clinical Oncology. Ann Oncol
10:1355-9, 1999.

60\. Gordon B, Lyden E, Lynch J, Tarantolo S, Pavletic ZS, **Bishop M**,
Reed E, Kessinger A, Haire W Central nervous system dysfunction as the
first manifestation of multiple organ dysfunction syndrome in stem cell
transplant patients. Bone Marrow Transplant 25:79-83, 2000.

61\. Bennett CL, Stinson TJ, Laver JH, **Bishop MR**, Godwin JE, Tallman
MS. Cost analyses of adjunct colony stimulating factors for acute
leukemia: Can they improve clinical decision making? Leuk Lymphoma.
37:65-70, 2000.

62\. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM,
Tarantolo SR, Stein RS, Bociek G, Greer JP, Wu CD, Kollath JP,
Weisenberger DD, Kessinger A, Wolff SN, Armitage JO, **Bishop MR**.
Outcome of allogeneic stem cell transplantation for B-CLL chronic
lymphocytic leukemia. Bone Marrow Transplant 25:717-22, 2000.

63\. **Bishop MR**, Tarantolo SR, Pavletic ZR, Lynch JC, Morris ME,
Zacharias D, Armitage JO, Kessinger A. Filgrastim as an alternative to
donor leukocyte infusion for relapse following allogeneic stem cell
tansplantaiton. J Clin Oncol 18:2269-72, 2000.

64\. **Bishop MR**, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Z.
Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger
A. A randomized double-blind trial of filgrastim (granulocyte
colony-stimulating factor) versus placebo following allogeneic blood
stem cell transplantation. Blood 96:80-4, 2000.

65\. Stinson TJ, Adams JR, **Bishop MR**, Kruse S, Tarantolo S, Bennett
CL. Economic Analysis of a Phase III Study of G-CSF versus Placebo
Following Allogeneic Blood Stem Cell Transplantation. Bone Marrow
Transplant 26:663-6, 2000.

66\. Mata JE, Jackson JD, Joshi SS, Tracewell WG, Pirruccello SJ, Murphy
BJ, **Bishop MR**, Iversen PL. Pharmacokinetics and in vivo effects of a
six-base phosphorothioate oligodeoxynucleotide with anticancer and
hematopoietic activities in swine. J Hematotherapy 9:205-14, 2000.

67\. Mata JE, **Bishop MR**, Tarantolo SR, Angel CR, Swanson SA, Iversen
PL. Evidence of enhanced iron excretion during systemic phosphorothioate
oligodeoxynucleotide treatment. J Toxicol Clin Toxicol 38:383-7, 2000.

68\. McCarthy NJ, **Bishop MR**. Nonmyeloablative allogeneic stem cell
transplantation: early promise and limitations. Oncologist 5:487-96,
2000 (invited review).

69\. Sharp JG, **Bishop MR**, Iversen PL. Oligonucleotide enhanced
cytotoxicity of idarubicin for lymphoma cells. Leukemia Lymphoma
42:417-27, 2001.

70\. **Bishop MR**. Non-myeloablative allogeneic stem cell
transplantation as adoptive cellular therapy. Principle Practice
Biologic Ther Cancer 2:1-9, 2001 (invited review).

71\. Joshi SJ, Lynch JC, Pavletic SZ, Tarantolo SR, Pirruccello SJ,
Kessinger A, **Bishop MR**. Decreased immune functions of blood cells
following mobilization with granulocyte colony-stimulating factor:
association with donor characteristics. Blood 98:1963-70, 2001.

72\. Weisdorf D, **Bishop M**, Dharan B, Bolwell B, Cahn JY, Cairo M,
Giralt S, Klein J, Lazarus H, Litzow M, Marks D, McCarthy P, Miller C,
Milone G, Russell J, Schultz KR, Sierra J, Wiernik P, Keating A,
Loberiza F, Kollman C, Horowitz M. Autologous versus allogeneic
unrelated donor transplantation for acute lymphoblastic leukemia:
comparative toxicity and outcomes. Biol Blood Marrow Transplant
8:213-20, 2002.

73\. Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, **Bishop MR**.
Pseudoautologous blood stem cell transplantation for refractory chronic
graft-versus-host disease. Bone Marrow Transplant 29:709-710, 2002.

74\. Khuu HM, Cowley H, David-Ocampo V, Carter CS, Kasten-Sportes C,
Wayne AS, Solomon SR, **Bishop MR**, Childs RM, Read EJ. Catastrophic
failures of freezing bags for cellular therapy products: description,
cause, and consequences. Cytotherapy 4:539-49, 2002.

75\. Fowler D, Hou J, Foley J, Hakim F, Odom J, Castro K, Carter C, Read
E, Gea-Banacloche J, Kasten-Sportes C, Kwak L, Wilson W, Levine B, June
C, Gress R, **Bishop M**. Phase I clinical trial of donor T-helper
Type-2 cells after immunoablative, reduced intensity allogeneic PBSC
transplant. Cytotherapy 4:429-30, 2002.

76\. Knutson KL, **Bishop MR**, Schiffman K, Disis ML. Immunotherapy for
breast cancer. Cancer Chemother Biol Response Modif. 20:351-69, 2002
(invited review).

77\. **Bishop MR**, Whit-Shan Hou J, Wilson WH, Steinberg SM, Odom J,
Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R,
and Fowler DH. Establishment of early donor engraftment after
reduced-intensity allogeneic hematopoietic stem cell transplantation to
potentiate the graft-versus-lymphoma effect against refractory
lymphomas. Biol Blood Marrow Transplant 9:162-9, 2003.

78\. Navolanic PM, Pui CH, Larson RA, **Bishop MR**, Pearce TE, Cairo
MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA.
Elitek(TM)-rasburicase: an effective means to prevent and treat
hyperuricemia associated with tumor lysis syndrome, a Meeting Report,
Dallas, Texas, January 2002. Leukemia 17:499-514, 2003.

79\. **Bishop MR**. Non-myeloablative allogeneic stem cell
transplantation for breast cancer. Clinical Breast Cancer 4:39-45, 2003.

80\. Dean RM, Bishop MR. Graft-versus-host disease: emerging concepts in
prevention and therapy. Curr Hematol Rep 2:287-94, 2003 (invited
review).

81\. **Bishop MR**. Graft-Versus-Lymphoma Effect: Fact, Fiction, or
Opportunity? J Clin Oncol 21:3713-5, 2003. (editorial)

82\. Joshi S, **Bishop M**, Lynch J, Tarantolo S, Abhyankar S, Bierman
P, Vose J, Geller R, McGuirk J, Foran J, Bociek R, Hadi A, Day S,
Armitage J, Kessinger A, Pavletic Z. Immunological and clinical effects
of post-transplant G-CSF versus placebo in T-cell replete allogeneic
blood transplant patients: results from a randomized double-blind study.
Cytotherapy 5:542-52, 2003.

83\. **Bishop MR**. The evolution of hematopoietic stem cell
transplantation for multiple sclerosis. Blood 102:2314, 2003.
(editorial)

84\. Fowler DH, **Bishop MR**, Gress RE. Immunoablative
reduced-intensity stem cell transplantation: potential role of donor Th2
and Tc2 cells. Sem Oncol 31:56-67, 2004.

85\. Kwak LW, Neelapu SS, **Bishop MR**. Adoptive immunotherapy with
antigen-specific T cells in myeloma: a model of tumor-specific donor
lymphocyte infusion. Semin Oncol 31:37-46, 2004. (invited review)

86\. Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT,
Fowler DH, **Bishop MR**, Pavletic SZ, Tamari M, Castro K, Barrett AJ,
Childs R, Illiei GG, Leitman SF, Malech HL, Horwitz ME. Severe Chronic
Graft-Versus-Host Disease is Characterized by a Preponderance of CD4+
Effector Memory Cells Relative to Central Memory Cells. Blood
103:2973--80, 2004.

87\. Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, **Bishop
MR**, Childs R, Barrett AJ, Csaky KG. Topical corticosteroid therapy for
cicatricial conjunctivitis associated with chronic graft-versus-host
disease. Bone Marrow Transplant 33:1031-5, 2004.

88\. Dean RM, **Bishop MR**. Allogeneic stem cell transplantation in
non-Hodgkin's lymphoma. Clin Lymphoma 4:238-49, 2004. (invited review).

89\. **Bishop MR**. Allogeneic hematopoietic stem cell transplantation
for breast cancer. Haematologica 89:599-605, 2004. (invited review)

90\. Fowler DH, Foley JE, Hou J, Odom J, Castro K, Steinberg SM,
Gea-Banacloche J, Kasten-Sportes C, Gress RE, **Bishop MR**. Clinical
\"cytokine storm\" as revealed by monocyte intracellular flow cytometry:
Correlation of TNF-alpha with severe gut graft-versus-host disease. Clin
Gastro Hepatology 2:237-45, 2004.

91\. **Bishop MR**, Steinberg SM, Marchigiani D, Kasten-Sportes C, Hardy
N, Dean R, Castro K, Hakim F, Read EJ, Carter C, Leitman SF, Gress RE,
Fowler DH. Ex-vivo T cell depleted allogeneic blood stem cell
transplantation after reduced intensity conditioning: effect of host T
cell depletion on engraftment. Br J Haematol 126:837-43, 2004.

92\. **Bishop MR**, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes
C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ,
Leitman S, Gress R. Allogeneic lymphocytes induce tumor regression of
advanced metastatic breast cancer. J Clin Oncol 22:3886-92, 2004.

93\. Cairo MS, **Bishop MR**. Tumor lysis syndrome. Br J Haematol
127:3-11, 2004.

94\. Walshe J, **Bishop MR**. Factors that affect engraftment of
allogeneic hematopoietic stem cells after reduced-intensity
conditioning. Cytotherapy 6:589-92, 2004.

95\. Pavletic SZ, Smith LM, **Bishop MR**, JC Lynch JC, Tarantolo SR,
Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A. Prognostic
Factors of Chronic Graft-versus-host Disease after Allogeneic Blood Stem
Cell Transplantation. Am J Hematol 78:265-74, 2005.

96\. Sportès C, McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D,
Kummar S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D,
**Bishop MR**, Fowler DH, Gress RE. Establishing a platform for
immunotherapy: Clinical outcome and study of immune reconstitution
following high-dose chemotherapy with progenitor cell support in breast
cancer patients. Biol Blood Marrow Transplant 11:472-83, 2005.

97\. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C,
Kasten-Sportes C, Gress RE, **Bishop MR**. Response to salvage
chemotherapy and outcome of reduced-intensity allogeneic stem cell
transplantation for non-Hodgkin's lymphoma: chemosensitive disease is
not required for durable survival. Biol Blood Marrow Transplant
11:593-9, 2005.

98\. Pavletic ZS, Khouri IF, Haagenson M, King RJ, Bierman PJ, **Bishop
MR**, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Roy V,
Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C.
Unrelated donor marrow transplantation for B-cell chronic lymphocytic
leukemia using myeloablative conditioning: results from the Center for
International Blood and Marrow Transplant Research. J Clin Oncol
23:5788-94, 2005.

99\. O'Mahoney D, **Bishop MR**. Monoclonal antibody therapy. Frontiers
in Bioscience 11:1620-35, 2006. (invited review).

100\. Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic
R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne
AS, Fowler DH, **Bishop MR**, Childs RW, Barrett AJ, Pavletic SZ, Malech
HL. Unique abnormalities of CD4(+) and CD8(+) central memory cells
associated with chronic graft-versus-host disease improve after
extracorporeal photopheresis. Biol Blood Marrow Transplant 12(1 Suppl
2):22-30, 2006.

101\. Tallman MS, Perez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM,
Marks DI, Cahn JY, Bashey A, **Bishop MR**, Christiansen N, Frankel SR,
Garcia JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger
S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez
RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A,
Weisdorf DJ, Horowitz MM. Pretransplantation consolidation chemotherapy
decreases leukemia relapse after autologous blood and bone marrow
transplants for acute myelogenous leukemia in first remission. Biol
Blood Marrow Transplant 12:204-16, 2006.

102\. Hardy NM, Daniel H. Fowler DH, **Bishop MR**. Immunotherapy of
Metastatic Breast Cancer: Phase I Trial of Reduced-Intensity Allogeneic
Hematopoietic Stem Cell Transplantation with Th2/Tc2 T-Cell Exchange.
Clin Breast Cancer 7:87-89, 2006.

103\. Bevans M, Marden S, Leidy NK, Soeken K, Cusack G, Rivera P,
Mayberry H, **Bishop MR**, Childs R and J Barrett J. Health-Related
Quality of Life in Patients Receiving Reduced Intensity Conditioning
Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow
Transplantation, 38:1-9, 2006.

104\. Yao K, Akyani N, Donati D, Sengamalay N, Fotheringham J, Ghedin E,
**Bishop M**, Barrett J, Kashanchi F, Jacobson S. Detection of HHV-6B in
post-mortem central nervous system tissue of a post-bone marrow
transplant recipient: a multi-virus array analysis. J Clin Virol
37(Suppl 1):S57-62, 2006.

105\. Fotheringham J, Akhyani N, Vortmeyer A, Donati D, Williams E, Oh
U, **Bishop M**, Barrett J, Gea-Banacloche J, Jacobson S. Detection of
active human herpesvirus-6 infection in the brain: correlation with
polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis
195:450-4. 2007.

106\. Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J,
Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C,
Mair R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE,
**Bishop MR**. Phase I Clinical Trial of Hematopoietic Stem Cell
Allograft Augmentation with Co-stimulated, IL-4 Polarized Donor CD4+ T
Cells. Biol Blood Marrow Transplant 12:1150-60, 2006.

107\. Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu O, Wu T,
Barrett AJ, **Bishop MR**, Childs RW, Fowler DH, Pavletic ZS, Thomas C.
Hart TC. Allogeneic Hematopoetic Stem Cell Transplantation is Associated
with Profound Changes in Salivary Proteome. Exp Hematol 35:184-92, 2007.

108\. Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS,
Stetler-Stevenson M, **Bishop MR**, Scheinberg DA, Rassenti L, Kipps TJ,
Kyle RA, Jelinek DF, Pastan I. Elevation of soluble CD307 (IRTA2/FcRH5)
protein in the blood and expression on malignant cells of patients with
multiple myeloma, chronic lymphocytic leukemia, and mantle cell
lymphoma. Leukemia 21:169-74, 2007.

109\. Nava VE, Cohen P, **Bishop M**, Fowler D, Jaffe ES, Ozdemirli M.
Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell
lymphoma. Am J Surg Pathol 31:476-80, 2007.

110\. Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R,
Odom J, Fowler D, Gress R, **Bishop MR**. Allograft T Cell-Depletion
Reveals Host Determinants of Early Donor T cell Engraftment and Recovery
after Reduced-Intensity Allogeneic Hematopoietic Stem Cell
Transplantation. Biol Blood Marrow Transplant 13:1022-30, 2007

111\. Stratton P, Turner ML, Childs R, Barrett AJ, **Bishop MR**, Wayne
A, Pavletic SZ. Vulvo-Vaginal Graft versus Host Disease: an unrecognized
problem responsive to topical glucocorticoid and hormone therapy. Obstet
Gynecol 110:1041-9, 2007

112\. Hardy NM, Grady C, Pentz R, Stetler-Stevenson M, Raffeld M,
Fontaine LS, Babb R, **Bishop MR**, Caporaso N, Marti GE. Bioethical
considerations of monoclonal B-cell lymphocytosis: donor transfer after
haematopoietic stem cell transplantation. Br J Haematol 139:824-831,
2007

113\. **Bishop MR**, Bolwell BJ, Cahn, JY, Gandham S, Giralt S,
Horowitz, MM, Keating A, Lazarus HH, Litzow MR, Loberiza, FL Jr., Marks
DJ, McCarthy PL, Miller C, Milone G, Russell JA, Sierra J, Wiernik PH,
Weisdorf D. Hematopoietic Stem Cell Transplantation for Adults with
Acute Lymphoblastic Leukemia: Comparative Analysis of Autologous and
Unrelated Donor Bone Marrow Transplantation. Bone Marrow Transplant 2007
Dec 17; \[Epub ahead of print\]

114\. Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA,
Dean R, **Bishop MR**, Gress RE, Hakim FT. Up-regulation of NK cell
activating receptors following allogeneic hematopoietic stem cell
transplantation under a lymphodepleting reduced intensity regimen is
associated with elevated IL-15 levels. Biol Blood Marrow Transplant
14:290-300, 2008

115\. Marks DI, Perez WS, He W, Zhang M-J, **Bishop MR**, Bolwell BJ,
Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski
AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy
PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH,
Weisdorf DJ. Unrelated Donor Stem Cell Transplantation for Adults with
Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in First
Complete Remission: A Center for International Blood and Marrow
Transplant Research Analysis. Blood 2008 \[Epub ahead of print\]

116\. Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ,
Fowler DH, **Bishop MR**, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley
R, Yau YY, Bolan CD. Donor demographic and laboratory predictors of
allogeneic peripheral blood stem cell mobilization in an ethnically
diverse population. Blood. 2008 Jun 3. \[Epub ahead of print\]

117\. **Bishop MR**, Dean RM, Steinberg S, Odom J, Pavletic SZ, Sportes
C, Hardy N, Pittaluga S, Gress RE, Fowler DH. Reduced-intensity
allogeneic stem cell transplantation for diffuse large B-cell lymphoma:
clinical evidence of a graft-versus-lymphoma effect. Ann Oncol 2008
\[Epub ahead of print\]

118\. Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom
J, Foley J, Gress R, **Bishop MR**. Association of serum interleukin-7
levels with the development of acute graft-versus-host disease. J Clin
Oncol (in press).

119\. Adelberg DE, **Bishop MR**. Emergencies related to systemic
treatment of cancer including chemotherapy and hematopoietic stem cell
transplantation. Emerg Med Clin North Am. (Invited review; in press).

Manuscripts in preparation:

1\. Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, **Bishop MR**.
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index
in non-Hodgkin's lymphoma patients receiving reduced-intensity
allogeneic hematopoietic stem cell transplantation. (submitted)

2\. **Bishop MR**, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic
SZ, Krumlauf M, Sportes C, Gress RH, Fowler DH. Differentiation of
chemotherapy sensitivity by disease state correlates with outcomes after
reduced-intensity allogeneic hematopoietic stem cell transplantation for
non-Hodgkin's lymphoma. (submitted)

3\. Fry TJ, Fowler D, Hakim F, Rager A, Memon S, Baird K, Delbrook CL,
**Bishop MR**, Gress RE, Mackall CL, Wayne AS. Preserved thymic function
results in rapid immune reconstitution after reduced intensity
allogeneic peripheral blood stem cell transplantation in pediatric
patients with malignancy. (submitted)

4\. Hardy NM, Dean RM, Odom J, Steinberg SM, Pavletic SZ, Chow C,
Sportes C, Krumlauf M, , Gea-Banacloche J, Gress RE, Fowler DH, **Bishop
MR**. Immunotherapy and Chemotherapy for Patients with Recurrent or
Progressive Non-Hodgkin's Lymphoma after Reduced-Intensity Allogeneic
Hematopoietic Stem Cell Transplantation.

5\. Hardy NM, Fellowes V, Memon S, Mariotti J, Carter C, Read EJ, Hakim
F, June C, Levine B, Gress R, Fowler D, **Bishop MR**. Novel Approaches
to Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell
Transplantation for Metastatic Breast Cancer: a Case Report.

6\. Dean RM, Hakim F, Fry T, Steinberg S, Boyiadzis M, Fowler DH, Odom
J, Mackall C, Gress RH, **Bishop MR**. Serum interleukin-7 and
interleukin-15 levels correlate with kinetics of immune reconstitution
following reduced-intensity allogeneic hematopoietic stem cell
transplantation.

7\. Dean RM, Fowler DH, Wilson WH, Hakim F, Fry T, Steinberg S, Odom J,
Chow C, Sportes C, Gea-Banacloche J, Pavletic S, Hardy N, Mackall C,
Gress RH, **Bishop MR**. Phase II clinical experience with a novel
regimen, EPOCH-Fludarabine, for disease control and immune depletion in
patients with lymphoproliferative disorders prior to reduced-intensity
allogeneic hematopoietic stem cell transplantation.

8\. **Bishop MR**, Dean RM, Hardy N, Hakim F, Steinberg S, Odom J,
Gea-Banacloche J, Gress RH, Fowler DH. Impact of donor T cells on
engraftment after reduced-intensity allogeneic hematopoietic stem cell
transplantation: a comparison of three methods of graft-versus-host
disease prophylaxis.

[Book Chapters]{.underline}:

1\. **Bishop MR** and Henslee-Downey PJ. \"Secondary Malignancy
following Bone Marrow Transplantation\", [Clinical Bone Marrow
Transplant: A Textbook]{.underline}, ed.: Atkinson, K. Cambridge
University Press, pp. 422-431, 1994

2\. **Bishop MR**, Warkentin PI, Jackson JD, Bayever E, Iversen PL,
Whalen VI, Lastovica J, Haines K, Kessinger A. "Antisense
Oligonucleotide OL(1)p53 for in vitro Purging of Autologous Bone Marrow
in Acute Myelogenous Leukemia", [Advances in Bone Marrow Purging and
Processing Fourth International Symposium]{.underline}, eds.: Gee A,
Gross S, Worthington-White D, Wiley-Liss, pp. 183-187, 1994.

3\. **Bishop MR**. "Mobilization Prior to Apheresis Procedure",
[Practical Considerations of Apheresis in Peripheral Blood Stem Cell
Transplantation]{.underline}, eds.: Kessinger A and McMannis JD. COBE
Laboratories, Inc., pp. 5-10, 1994.

4\. Rana TM and **Bishop MR**. \"Acute Lymphocytic Leukemia\", [Current
Therapy in Cancer]{.underline}, ed: Foley JF, Vose JM, Armitage JO. W.B.
Saunders, pp.315-321, 1994.

5\. **Bishop MR**. \"Gene Therapy\", [Current Therapy in
Cancer]{.underline}, eds.: Foley JF, Vose JM, Armitage JO. W.B.
Saunders, pp. 392-394, 1994.

6\. Armitage JO, [Bishop MR]{.underline}. \"Bone Marrow
Transplantation.\" [Clinical Oncology]{.underline}, ed.: Abeloff MD,
Armitage JO, Lichter AS, Niederhuber JE. Churchill Livingston, pp.
295-305, 1995.

7\. **Bishop MR** and Coccia PF. \"Tumor Lysis Syndrome.\" [Clinical
Oncology]{.underline}, ed.: Abeloff MD, Armitage JO, Lichter AS,
Niederhuber JE. Churchill Livingston, pp. 557-561, 1995.

8\. Bierman PJ, **Bishop MR**, and Armitage JO. "High-dose Chemotherapy
with Cellular Support for Hematological Malignancies, [Cell
Therapy]{.underline}, eds.: Morstyn G, Sheridan W. Cambridge University
Press, pp. 337-351, 1995.

9\. Iversen PL, Copple BL, Tewary HK, Bayever E, and **Bishop MR**.
"Continuous Infusion of Antisense Phosphorothioate Therapeutics",
[Methods in Molecular Medicine: Antisense Therapeutics]{.underline},
ed.: Agrawal S. Humana Press Inc., 11:201-212, 1996.

10\. Sharp JG, Bishop M, Chan WC, Greiner T, Joshi SS, Kessinger A, Reed
E, Sanger W, Tarantolo S, Traystman M, and Vose J. "Detection of Minimal
Residual Disease in Hematopoietic Tissues", [Bone Marrow
Transplantation: Foundations for the 21st Century]{.underline}, eds.:
Sackstein R, Janssen WE, Elfenbein GJ. New York Academy of Science, New
York, NY, 770:242-261, 1995.

11\. Armitage JO and **Bishop MR**. "Bone Marrow Transplantation",
[Yearbook of Cell and Tissue Transplantation]{.underline}, eds.: Lanza
RP, Chick WL. Netherlands: Kluwer Academic Publishers, 3-12, 1996/97.

12\. **Bishop, MR**. "Bone Marrow Transplantation from Unrelated
Donors", [American Society of Clinical Oncology Education
Book]{.underline}, ed. Perry M. American Society of Clinical Oncology,
Alexandria, VA, 1998.

13\. Malone JM III, and **Bishop MR**. \"Acute Lymphocytic Leukemia\",
[Current Therapy in Cancer]{.underline} (second edition), eds.: Foley
JF, Vose JM, Armitage JO. W.B. Saunders, 1999.

14\. **Bishop MR**. "Stem Cell Transplantation for Chronic Myelogenous
Leukemia: Indications and Timing" In: Current Controversies in Bone
Marrow Transplantation. ed.: Bolwell BJ. Humana Press. pp. 83-94, 1999.

15\. Sanger WG and **Bishop MR**. "Cytogenetics." [Malignant
Lymphoma]{.underline}, eds.: Hancock, Selby, MacLennan and Armitage,
Chapman & Hall Ltd, 2000.

16\. **Bishop MR** and Coccia PF. \"Tumor Lysis Syndrome\" [Clinical
Oncology]{.underline} (second edition), eds.: Abeloff MD, Armitage JO,
Lichter AS, Niederhuber JE. Churchill Livingston, 2000.

17\. **Bishop MR**. \"Non-Myeloablative Allogeneic hematopoietic Stem
Cell Transplantation as Adoptive Cellular Therapy\"; [Updates:
Principles and Practice of Biologic Therapy of Cancer]{.underline}
(Third edition), ed.: Rosenberg SA. Lippincollt, Williams, & Wilkins,
2001

18\. **Bishop MR** and Henslee-Downey PJ. \"Secondary Solid Tumors
following Hematopoietic Stem Cell Transplantation\", [Clinical Bone
Marrow Transplant: A Textbook]{.underline} (Third Edition), ed.:
Atkinson, K. Cambridge University Press, 2003.

19\. **Bishop MR** and Fowler DH. "Adoptive Immunotherapy for Malignant
Disease", [American Society of Clinical Oncology Education
Book]{.underline}, ed. Perry M. American Society of Clinical Oncology,
Alexandria, VA; pp. 22-8, 2003.

20\. **Bishop MR**. "Non-myeloablative Allogeneic Hematopoietic Stem
Cell Transplantation for Solid Tumors", [American Society of Clinical
Oncology Education Book]{.underline}, ed. Perry M. American Society of
Clinical Oncology, Alexandria, VA; pp. 256-65, 2003.

21\. **Bishop MR**, Cairo M and Coccia PF. \"Tumor Lysis Syndrome\",
[Clinical Oncology]{.underline} (Third edition), eds.: Abeloff MD,
Armitage JO, Lichter AS, Niederhuber JE. Churchill Livingston) pp.
987-992, 2004.

22\. Hardy NM and **Bishop MR**. "Harnessing the Potential of
Graft-versus-Tumor", [Immunotherapy of Cancer]{.underline}, ed.: Disis
ML, Humana Press Totowa, NJ; pp. 235 -- 261, 2006

23\. **Bishop MR**. "Principles of Hematopoietic Stem Cell
Transplantation to Treat Hematologic Malignancies", [Clinical Neoplastic
Hematology]{.underline}, eds.: Bolwell B, Kalaycio M, Sekeres M.
McGraw-Hill Professional (in press).

24\. Rader C and **Bishop MR**. "Monoclonal Antibodies in Cancer
Therapy", [General Principles of Tumor Immunotherapy: Basic and General
Applications of Tumor Immunology]{.underline}, eds.: Kaufman HL and
Wolchok JD. Kluwer Academic Publishers. (in press)

25\. Boyiadzis MM and **Bishop MR**. "Complications and Follow-up after
Hematopoietic Stem Cell Transplantation", [Hematology-Oncology
Therapy]{.underline}, ed.: Boyiadzis MM, Lebowitz PF, Frame JN, Fojo T.
McGraw-Hill Professional; pp. 674-693, 2007

26\. Barrett AJ, Chao NJ, and **Bishop MR**. "Allogeneic Stem Cell
Transplantation: Are We Curing More Patients?" [American Society of
Clinical Oncology Education Book]{.underline}, ed. Perry M. American
Society of Clinical Oncology, Alexandria, VA; pp.387-96, 2006

27\. Hardy NM and **Bishop MR**. "The Place of Stem Cell Transplantation
in the Treatment of Breast Cancer", [The Clinical Practice of Stem Cell
Transplantation]{.underline} (Second edition), eds.: Treleaven J,
Barrett AJ. Elsevier (in press).

28\. Pavletic SZ and **Bishop MR**. \"Hematopoietic Stem Cell
Transplantation\", [Clinical Oncology]{.underline} (Fourth edition),
eds.: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Churchill
Livingston) pp. (in press).

29\. Giralt S and **Bishop MR**. "Principles and Overview of Allogeneic
Hematopoietic Stem Cell Transplantation", [Hematopoietic Stem Cell
Transplantation]{.underline} (ed. **Bishop MR**. Springer) (in press).

[Books]{.underline}:

1\. Introduction and scientific editor for "Living with Lymphoma" by
Adler EM, The John Hopkins University Press, Baltimore, 2005

2\. Hematopoietic Stem Cell Transplantation. Series: [Cancer Treatment
and Research]{.underline}, **Bishop MR** (Editor). Springer, New York
(in preparation).

**Revised June 23, 2008**